• Explore /
  • Poster
  • / A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.

A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.

Abstract Poster

Authors

null

Carlos Becerra

Internal Medicine, Sammons Cancer Center, Dallas, TX

Carlos Becerra , Jeffrey R. Infante , Lawrence E. Garbo , Michael S. Gordon , David A. Smith , Fadi S. Braiteh , David R. Gandara , Robert M. Jotte , Karen L. Reckamp , Filip Janku , Howard A. Burris III, Kevin M. Bellew , Olivia S. Gardner , Li Liu , Donna S Cox , Vijay Gopal Reddy Peddareddigari , George R. Blumenschein Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics - Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

Signal Transduction

Clinical Trial Registration Number

NCT01192165

Citation

J Clin Oncol 30, 2012 (suppl; abstr 3023)

DOI

10.1200/jco.2012.30.15_suppl.3023

Abstract #

3023

Poster Bd #

15

Abstract Disclosures

Similar Posters

First Author: Serena Marchetti

First Author: Funda Meric-Bernstam

First Author: Quincy S. Chu

First Author: Soohyeon Lee